Varun Monga, MD, clinical associate professor, internal medicine, hematology, oncology, and blood and marrow transplantation, University of Iowa, discusses the background for investigating the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in a phase 1 study (NCT04089449) in patients with recurrent high-grade glioma or uveal melanoma, as well as the agent’s mechanism of action.
2023
High-Risk Resected Melanoma
In a retrospective cohort study reported in JAMA Network Open, Goodman et al found that patients receiving adjuvant PD-1 inhibitor therapy for high-risk resected melanoma often had chronic immune-related adverse events, with some persisting over long-term follow-up.
Hashimoto Thyroiditis: Nonsignificant Risk Factor in Melanoma, Other Skin Cancer
Hashimoto thyroiditis (HT) is not a significant risk factor for melanoma or nonmelanoma skin cancer (NMSC), according to study results published in the Archives of Dermatological Research.
Chronic immune-related adverse events common after anti-PD-1 therapy for melanoma
Nearly two-thirds of patients experienced acute immune-related adverse events.